Treatment | Day of treatment or re-infestation | ||||||
---|---|---|---|---|---|---|---|
0 | 7 | 14 | 21 | 28 | 35 | ||
Placebo | Range | 40–95 | 33–79 | 60–89 | 48–88 | 56–85 | 62–95 |
A. mean | 62.3 | 59.5 | 74.6 | 75.8 | 70.0 | 80.4 | |
G. mean1 | 60.4a | 57.0a | 74.1a | 74.7a | 69.3a | 79.8a | |
Sarolaner | Range | 0–0 | 0–2 | 0–0 | 0–0 | 0–0 | 0–0 |
A. mean | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | |
Efficacy (%) | 100 | 99.6 | 100 | 100 | 100 | 100 | |
G. mean1 | 0.0b | 0.1b | 0.0b | 0.0b | 0.0c | 0.0c | |
Efficacy (%) | 100 | 99.7 | 100 | 100 | 100 | 100 | |
P-value vs.placebo | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | |
Afoxolaner | Range | 0–0 | 0–2 | 0–2 | 0–4 | 0–28 | 0–25 |
A. mean | 0.0 | 0.3 | 0.3 | 0.9 | 5.5 | 4.3 | |
Efficacy (%) | 100 | 99.6 | 99.7 | 98.8 | 92.1 | 94.7 | |
G. mean1 | 0.0b | 0.1b | 0.1b | 0.5b | 2.5b | 1.4b | |
Efficacy (%) | 100 | 99.7 | 99.8 | 99.4 | 96.4 | 98.2 | |
P-value vs. placebo | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | |
P-value vs. sarolaner | 1.000 | 1.000 | 0.2455 | 0.0713 | 0.0008 | 0.0161 |